A case of successfully resected metachronous gastric and gallbladder metastases from pancreatic body cancer
Pancreatic ductal adenocarcinoma (PDAC) readily metastasizes to the lymph nodes, liver, lung, and peritoneum; however, gastric and gallbladder metastases are rare. We report a case of metachronous gastric and gallbladder metastases from PDAC.
The patient is a 71-year-old man who underwent distal pancreatectomy for PDAC. Seventeen months after the surgery, a 30-mm nodule was detected at the lesser curvature of the stomach, which was diagnosed as recurrence of PDAC in the lymph nodes. He then received gemcitabine and S-1 combination chemotherapy for 6 months. Because tumor size remained approximately the same and tumor marker levels decreased, total gastrectomy and cholecystectomy were performed. Pathological examination showed well-differentiated tubular adenocarcinoma in the subserosa and muscularis propria of the stomach and gallbladder. The patient remains alive at 41 months after the second surgery with liver metastasis.
We reported a rare case of metachronous gastric and gallbladder metastases from pancreatic body cancer.
KeywordsPancreatic cancer Metachronous gastric metastasis Metachronous gallbladder metastasis Surgery
Prognosis in patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal, with a 5-year survival rate below 10% [1, 2]. The lymph nodes, liver, lung, and peritoneum are the predominant sites of metastasis; however, gastric and gallbladder metastases are very rare. We describe a case of metachronous gastric and gallbladder metastases from pancreatic body cancer.
Based on these findings, we diagnosed lymph node metastasis of PDAC invading the gastric wall, and the patient was treated with gemcitabine and S-1 combination (GS) therapy for 6 months. Considering the patient’s age and prior pancreatic resection, we selected GS therapy due to its relatively high response rate and manageable complication rate found in a previous phase III study for unresectable pancreatic cancer (GEST study) . Because the tumor size did not change over 6 months and CA 19-9 decreased from 54 to 28 U/mL, we decided to perform total gastrectomy and prophylactic cholecystectomy for tumor resection.
Surprisingly, there was a tumor in the neck of gallbladder; pathological examination revealed this was a well-differentiated tubular adenocarcinoma in the subserosa (Fig. 3c, d).
As the pathological findings of these tumors were similar to the lesion initially resected by distal pancreatectomy, we diagnosed metachronous gastric and gallbladder metastases from PDAC.
The patient’s postoperative course was uneventful, and the patient was discharged on postoperative day 16. Because of prior S-1 adjuvant therapy after pancreatectomy and GS therapy before gastrectomy/cholecystectomy, we elected to defer further chemotherapy. A liver metastasis was discovered 7 months after the second operation. He was then treated with GS therapy followed by gemcitabine and albumin-bound paclitaxel combination therapy and modified FOLFIRINOX therapy. At 41 months after the second surgery, the patient remained alive.
Previous studies have noted that the predominant sites of metastasis for PDAC are the lymph node, liver, lung, and peritoneum [4, 5]. We described a rare case of metachronous gastric and gallbladder metastases from pancreatic body cancer. Gastric metastasis of PDAC is rare. To our knowledge, only three cases have been reported in the English literature [6, 7, 8]. Oda et al. performed autopsies on 209 patients with PDAC and reported that gastric metastasis was found in only two cases .
Generally speaking, there are five metastatic pathways to the stomach: (1) direct invasion, (2) intraoperative seeding, (3) hematogenous metastasis, (4) lymphatic metastasis, and (5) intraluminal or intramural dissemination . In our case, the primary pancreatic tumor was not anatomically near the stomach, and resection with tumor-free margins was performed. In addition, the two metastatic lesions in the subserosa and muscularis propria of the stomach did not expose to the mucosa or serosa. Considering these facts, we thought that gastric metastasis occurred through the hematogenous pathway.
Gallbladder metastasis of PDAC is also rare. This appears to be the first report of resected gallbladder metastasis from PDAC in the English literature. An autopsy study by Kishi et al. demonstrated a 7.4% incidence of gallbladder metastasis among patients with PDAC . Yoon et al. surveyed 417 patients with pathologically confirmed gallbladder malignancies; 20 (4.8%) were metastatic (stomach, n = 8; colorectum, n = 3; liver, kidney, and skin, n = 2 each; and others, n = 3) . In our case, as the tumor was subserosal and did not expose to the mucosa, hematogeneous metastasis was most likely, as with the gastric metastases. Although Yoon et al. also reported that the prognosis of metastatic gallbladder carcinoma was poor, with 8.7 months of median overall survival , our case resulted in long-term survival after surgical resection.
There was a possibility that cancer cell seeding by FNA was the cause of gastric metastases. However, we think it unlikely because one of the metastases was located in the antrum, far from the aspiration site, and we also found a gallbladder metastasis which could not have been related to FNA.
Surgical resection for disease relapse of PDAC remains debatable due to lack of evidence of survival benefit. Recently, several studies showed survival benefit of surgical resection for PDAC recurrence. Miyazaki et al. showed a prolonged survival by repeat pancreatomy for isolated local recurrence . Thomas et al. highlighted a single tumor as a key factor benefiting most from re-resection for lung metastasis from PDAC .
In the case presented here, we first diagnosed solitary lymph node recurrence of PDAC after pancreatectomy by CT imaging and performed surgical resection after chemotherapy. Unintentionally, two gastric metastases and one gallbladder metastasis were resected with tumor-free margins. This patient’s survival of more than 3 years suggests the benefit of surgical intervention in combination with systemic chemotherapy. However, specific selection criteria for resection for multiple metastases remain unclear.
We reported a case of surgically resected metachronous gastric and gallbladder metastases from pancreatic body cancer. Further studies of surgical resection of PDAC recurrence are needed.
Availability of data and materials
Data sharing is applicable to this article.
MT drafted the manuscript. HY, AK, KF, TT, SK, ST, MM, and MO contributed in the preoperative check and diagnosis. HY, SK, MT, and KK performed the operation. HY and ST followed up the patient. KS diagnosed the disease as pathologists. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Informed consent was obtained from the patient for the publication of this case report.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clini Oncol. 2013;31(13):1640–8.CrossRefGoogle Scholar
- 11.Kishi KHT, Nakamura K, Yoshimori M, Ohkura H, Ozaki H. Carcinoma of the pancreas: a review of 94 autopsy cases. Jpn J Clin Oncol. 1980;10(2):273–9.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.